Active ingredient: Amlodipine; Hydrochlorothiazide; Valsartan 

 

Form/Route: Tablets /Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 

Design: Single-dose, two-way crossover in-vivo 

Strength: 10 mg/25 mg/320 mg 

Subjects: Healthy males and nonpregnant females, general population. 

Additional Comments: 




___________________________________________________________________________ 

 

2. Type of study: Fed 

Design: Single-dose, two-way crossover in-vivo 

Strength: 10 mg/25 mg/320 mg 

Subjects: Healthy males and nonpregnant females, general population. 

Additional Comments: 




__________________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): Amlodipine, Hydrochlorothiazide, 
Valsartan in plasma 

 

Bioequivalence based on (90% CI): Amlodipine, Hydrochlorothiazide, Valsartan 

 

Waiver request of in-vivo testing: 5 mg/12.5 mg/160 mg, 10 mg/12.5 mg/160 mg, 5 mg/25 
mg/160 mg and 10 mg/25 mg/160 mg on (i) acceptable bioequivalence studies on the 10 mg/25 
mg/320 mg, (ii) acceptable dissolution testing across all strengths, and (iii) proportional similarity in the 
formulations across all strengths 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.accessdata.fda.gov/ scripts/cder/dissolution/. Please find the dissolution 
information for this product at this website. Please conduct comparative dissolution testing on 12 
dosage units each of all strengths of the test and reference products. Specifications will be 
determined upon review of the application. 


